 MONT-SAINT-GUIBERT, Belgium, July 20, 2021 GLOBE NEWSWIRE -- Celyad Oncology SA Euronext Nasdaq: CYAD Celyad Oncology or the Company, a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell CAR T therapies for cancer, highlighted a new preclinical allogeneic armored CAR T candidate developed from its shRNA platform and data updates to the shRNA-based allogeneic candidate CYAD-211 for rr MM and allogeneic candidate CYAD-101 for mCRC today during a research and development day hosted by the Companys management team. 